BioLargo, Inc. Files 8-K Report

Ticker: BLGO · Form: 8-K · Filed: Aug 15, 2024 · CIK: 880242

Sentiment: neutral

Topics: sec-filing, 8-k, regulation-fd

TL;DR

BioLargo filed an 8-K, likely with financial updates. Keep an eye out for details.

AI Summary

On August 14, 2024, BioLargo, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates that BioLargo, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification and does not contain information that inherently increases risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by BioLargo, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to include Financial Statements and Exhibits.

What is the exact date of the earliest event reported in this filing?

The date of the earliest event reported is August 14, 2024.

What is BioLargo, Inc.'s principal executive office address?

BioLargo, Inc.'s principal executive office is located at 14921 Chestnut St., Westminster, California 92683.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is BioLargo, Inc.'s state of incorporation and IRS Employer Identification Number?

BioLargo, Inc. is incorporated in Delaware and its IRS Employer Identification Number is 65-0159115.

Filing Stats: 584 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-08-14 19:47:33

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. BioLargo, Inc., presented the slides attached as Exhibit 99.1 , which are incorporated herein by reference, on May 14, 2024, at 1:30 PM Pacific Time, at a webcast investor conference. The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the slide presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the information under the heading "Safe Harbor Act" in Exhibit 99.1 attached hereto.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Slide deck presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 14, 2024 BIOLARGO, INC. By: /s/ Dennis P. Calvert Dennis P. Calvert President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing